FY2030 Earnings Estimate for TSE:ONC Issued By HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at HC Wainwright cut their FY2030 earnings estimates for shares of Oncolytics Biotech in a research report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.19 per share for the year, down from their prior forecast of $0.25. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Stock Performance

Shares of ONC stock opened at C$14.90 on Wednesday. Oncolytics Biotech has a 12 month low of C$0.44 and a 12 month high of C$2.08. The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company’s fifty day moving average price is C$14.90 and its two-hundred day moving average price is C$14.90.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.